Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study

被引：0
|
作者：
Bourhis, J. [1 ]
Sun, X. [2 ]
Pointreau, Y. [3 ]
Sire, C. [4 ]
Le Tourneau, C. [5 ]
Coutte, A. [6 ]
Kaminsky-Forrett, M-C. [7 ]
Alfonsi, M. [8 ]
Boisselier, P. [9 ]
Martin, L. [10 ]
Delord, J-P. [11 ]
Clatot, F. [12 ]
Miroir, J. [13 ]
Rolland, F. [14 ]
Crompton, P. [15 ]
Brienza, S. [15 ]
Szyldergemajn, S. A. [15 ]
Even, C. [16 ]
Tao, Y. [17 ]
机构：
[1] CHU Vaudois, Radiat Oncol, Lausanne, Switzerland
[2] HNFC, Radiat Oncol, Belfort, France
[3] Ctr Jean Bernard, Radiat Oncol, Le Mans, France
[4] Hop Scorff, Ctr Hosp Bretagne Sud, Radiat Oncol, Lorient, France
[5] Inst Curie, Med Oncol, Paris, France
[6] CHU Amiens Picardie Site Nord, Oncol Radiotherapy, Amiens, France
[7] Inst Cancerol Lorraine Alexis Vautrin, Radiat Oncol, Vandoeuvre Les Nancy, France
[8] Inst Ste Catherine, Radiat Oncol, Avignon, France
[9] ICM Reg Canc Inst Montpellier, Radiat Oncol, Montpellier, France
[10] Ctr Radiotherapie Gillaume Le Conquerant, Radiat Oncol, Le Havre, France
[11] Inst Univ Canc Toulouse Oncopole, Med Oncol, Toulouse, France
[12] Ctr Henri Becquerel, Med Oncol, Rouen, France
[13] Ctr Jean Perrin, Radiat Oncol, Clermont Ferrand, France
[14] ICO Inst Cancerol Ouest Rene Gauducheau, Radiat Oncol, St Herblain, France
[15] Debiopharm Int SA, CR&D, Lausanne, Switzerland
[16] Inst Gustave Roussy, Med Oncol, Villejuif, France
[17] Inst Gustave Roussy, Radiat Oncol, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA65
引用
收藏
页码：902 / 902
页数：1
相关论文
共 50 条
  • [21] PHASE I STUDY OF CONCURRENT PEMETREXED, CETUXIMAB AND RADIATION THERAPY WITH OR WITHOUT CISPLATIN IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    Licitra, L.
    Bergamini, C.
    Olmi, P.
    Soldatenkova, V.
    Ameryckx, S.
    Russo, F.
    ANNALS OF ONCOLOGY, 2010, 21 : 320 - 320
  • [22] Multi-Institutional Randomized Double-Blind Phase II Trial of Everolimus vs. Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
    Nathan, C. A. O.
    Hayes, D. N.
    Harismendy, O.
    Flores, J.
    Moore-Medlin, T.
    Gutkind, J. S.
    Neupane, P.
    Mills, G.
    Sargi, Z. B.
    Seiwert, T. Y.
    Grilley-Olson, J.
    Day, T.
    Gillison, M.
    Wade, J.
    Feldman, L.
    Jha, G.
    Kozloff, M.
    O'Leary, M.
    Worden, F.
    Cohen, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1116 - 1116
  • [23] Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin
    Takahashi, Toshiaki
    Hoshi, Eishin
    Takagi, Masakazu
    Katsumata, Noriyuki
    Kawahara, Masaaki
    Eguchi, Kenji
    CANCER SCIENCE, 2010, 101 (11) : 2455 - 2461
  • [24] Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
    Harrington, Kevin
    Temam, Stephane
    Mehanna, Hisham
    D'Cruz, Anil
    Jain, Minish
    D'Onofrio, Ida
    Manikhas, Georgy
    Horvath, Zsuzsanna
    Sun, Yan
    Dietzsch, Stefan
    Dubinsky, Pavol
    Holeckova, Petra
    El-Hariry, Iman
    Franklin, Natalie
    Biswas-Baldwin, Nigel
    Legenne, Philippe
    Wissel, Paul
    Netherway, Thelma
    Farrell, John
    Ellis, Catherine
    Wang-Silvanto, Jing
    Amonkar, Mayur
    Ahmed, Nazma
    Santillana, Sergio
    Bourhis, Jean
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) : 4202 - +
  • [25] Phase II trial of chemoradiotherapy concurrent with S-1 plus cisplatin in patients with unresectable, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results of the Japan Clinical Oncology Group study, JCOG 0706
    Tahara, Makoto
    Kiyota, Naomi
    Mizusawa, Junki
    Nakamura, Kenichi
    Hayashi, Ryuichi
    Akimoto, Tetsuo
    Hasegawa, Yasuhisa
    Iwae, Shigemichi
    Monden, Nobuya
    Matsuura, Kazuto
    Fujii, Hirofumi
    Onozawa, Yusuke
    Homma, Akihiro
    Kubota, Akira
    Fukuda, Haruhiko
    Fujii, Masato
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] PHASE II TRIAL OF CHEMORADIOTHERAPY CONCURRENT WITH S-1 PLUS CISPLATIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN): RESULTS OF THE JAPAN CLINICAL ONCOLOGY GROUP STUDY, JCOG 0706
    Fujii, M.
    Tahara, M.
    Kiyota, N.
    Mizusawa, J.
    Nakamura, K.
    Hayashi, R.
    Akimoto, T.
    Hasegawa, Y.
    Iwae, S.
    Monden, N.
    Matsuura, K.
    Fujii, H.
    Onozawa, Y.
    Homma, A.
    Kubota, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 36 - 36
  • [27] Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
    Tao, Y.
    Biau, J.
    Sun, X. S.
    Sire, C.
    Martin, L.
    Alfonsi, M.
    Prevost, J. B.
    Modesto, A.
    Lafond, C.
    Tourani, J. M.
    Miroir, J.
    Kaminsky, M. C.
    Coutte, A.
    Liem, X.
    Chautard, E.
    Vauleon, E.
    Drouet, F.
    Ruffer, A.
    Ramee, J. F.
    Waksi, G.
    Pechery, A.
    Wanneveich, M.
    Guigay, J.
    Auperin, A.
    Bourhis, J.
    ANNALS OF ONCOLOGY, 2023, 34 (01) : 101 - 110
  • [28] A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.
    Pearson, Alexander T.
    Seiwert, Tanguy Y.
    Cohen, Roger B.
    Saba, Nabil F.
    Kaczmar, John M.
    Fidler, Mary J.
    Wade, James L., III
    Castellucci, Enrico
    Karrison, Theodore
    Katipally, Rohan Reddy
    Juloori, Aditya
    Rosenberg, Ari Joseph
    Haraf, Daniel J.
    Agrawal, Nishant
    Vokes, Everett E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial
    Fayette, J.
    Thomas, G.
    Daste, A.
    Rotarski, M.
    Castelo, B.
    Rullan, A.
    Levine, A.
    Philipson, R. S.
    Harrington, K. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S615 - S616
  • [30] Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?
    Haddad, Robert I.
    Harrington, Kevin
    Tahara, Makoto
    Szturz, Petr
    Le Tourneau, Christophe
    Salmio, Satu
    Bajars, Marcis
    Lee, Nancy Y.
    CANCER TREATMENT REVIEWS, 2023, 119
12345